<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIM: To estimate absolute and relative incidence rates of <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> when using once-daily evening or morning regimens of insulin glargine (glargine) versus once-daily evening <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NPH</z:e> insulin (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NPH</z:e>) using individual patient data (IPD) </plain></SENT>
<SENT sid="1" pm="."><plain>MATERIALS AND METHODS: Randomized controlled trials with accessible IPD and including white European people with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> (T2DM) using glargine or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NPH</z:e> once-daily (with oral <z:chebi fb="105" ids="17234">glucose</z:chebi>-lowering drugs) were identified </plain></SENT>
<SENT sid="2" pm="."><plain>Two study pools were analysed: evening glargine versus evening <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NPH</z:e> (pool 1); and morning glargine versus evening <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NPH</z:e> (pool 2) </plain></SENT>
<SENT sid="3" pm="."><plain>The number-needed-to-treat to avoid <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> was calculated for glargine versus <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NPH</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: In study pool 1 (n = 2711), the risk of nocturnal <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> was approximately halved with glargine compared with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NPH</z:e> [odds ratios (OR): 0.44-0.52, p &lt; 0.001-0.047] </plain></SENT>
<SENT sid="5" pm="."><plain>This led to a significant reduction in anytime risk of symptomatic <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> [plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> (PG) &lt;3.9 mmol/l, OR: 0.64, p = 0.018; PG &lt;2.0 mmol/l, OR: 0.51, p &lt; 0.001] </plain></SENT>
<SENT sid="6" pm="."><plain>In study pool 2 (n = 470), although a strong numerical reduction in <z:hpo ids='HP_0000001'>all</z:hpo> types of nocturnal <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> was observed (OR: 0.16-0.64), statistical significance was reached only for symptomatic <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> with PG &lt;3.9 mmol/l (p &lt; 0.001) </plain></SENT>
<SENT sid="7" pm="."><plain>Eight (pool 1) or five (pool 2) people with T2DM needed to use glargine rather than <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NPH</z:e> to avoid one person from experiencing a nocturnal symptomatic hypoglycaemic event within a median of about 25 weeks of starting insulin </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: This meta-analysis of open-label studies provides confidence that reductions of around 50% of risk for nocturnal <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> can be achieved with using glargine instead of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NPH</z:e> </plain></SENT>
</text></document>